Loading...
Market
Who will lead the obesity treatment market by end of 2025?
2
Resolution / Starting Odds
Viking Therapeutics • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Other • 25%
Market analysis reports from firms like Statista or Grand View Research
Story
Viking Therapeutics' Obesity Pill Shows 8.2% Weight Loss, Stock Surges 20%
Nov 4, 2024, 01:52 AM
Viking Therapeutics' experimental obesity pill, VK2735, has shown promising results in recent studies. The oral formulation demonstrated a weight loss of 8.2% and 6.8% in separate trials, with safety and tolerability comparable to a placebo. The drug's efficacy and safety profile position it as a potential competitor to existing treatments from Novo Nordisk and Eli Lilly. Viking's market cap is around $10 billion, with the total addressable market for obesity treatments estimated at over $200 billion. The company's stock surged 20% in overnight trading following the release of the data. The 28-day Phase 1 trial showed positive results even at a 100mg dose. Future trials are expected to further validate the drug's effectiveness and safety.
View original story
Similar markets
MariTide leads market share • 25%
Eli Lilly leads market share • 25%
Novo Nordisk leads market share • 25%
Market share is evenly distributed • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Roche's CT-996 has the largest market share • 25%
Novo Nordisk has the largest market share • 25%
Eli Lilly has the largest market share • 25%
Other companies have the largest market share • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
GlaxoSmithKline • 25%
Other • 25%
Zepbound • 25%
Wegovy • 25%
Saxenda • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
None of the above • 25%